Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $381.46

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have earned an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $381.4615.

Several equities research analysts have issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $420.00 price target on shares of BeOne Medicines in a research note on Monday, November 17th. Citigroup raised their price objective on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a report on Monday, November 10th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a research note on Wednesday, December 17th. Citizens Jmp increased their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Finally, Sanford C. Bernstein raised shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target on the stock in a research note on Monday, January 12th.

BeOne Medicines Stock Performance

BeOne Medicines stock opened at $362.14 on Wednesday. BeOne Medicines has a fifty-two week low of $196.45 and a fifty-two week high of $385.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The stock has a market cap of $39.71 billion, a P/E ratio of 710.08 and a beta of 0.52. The firm’s fifty day moving average price is $333.08 and its 200-day moving average price is $328.68.

Insider Buying and Selling

In other BeOne Medicines news, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John Oyler sold 75,631 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $307.79, for a total value of $23,278,465.49. Following the transaction, the chief executive officer directly owned 24,369 shares in the company, valued at $7,500,534.51. This trade represents a 75.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 105,283 shares of company stock worth $32,463,041 in the last 90 days. 6.62% of the stock is owned by company insiders.

Institutional Trading of BeOne Medicines

Institutional investors have recently made changes to their positions in the stock. Compound Planning Inc. bought a new position in shares of BeOne Medicines in the fourth quarter worth approximately $223,000. Invesco Ltd. boosted its position in BeOne Medicines by 1,008.6% during the 4th quarter. Invesco Ltd. now owns 14,123 shares of the company’s stock valued at $4,291,000 after buying an additional 12,849 shares during the period. Corient Private Wealth LLC grew its holdings in BeOne Medicines by 25.9% in the 4th quarter. Corient Private Wealth LLC now owns 1,064 shares of the company’s stock worth $323,000 after acquiring an additional 219 shares during the last quarter. Vident Advisory LLC increased its position in shares of BeOne Medicines by 20.4% in the fourth quarter. Vident Advisory LLC now owns 2,052 shares of the company’s stock valued at $623,000 after acquiring an additional 347 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of BeOne Medicines during the fourth quarter valued at about $2,912,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.